English

AMAG PHARMACEUTICALS, INC.

EDGAR

AMAG Quarterly report (10-Q) · filed 2020-11-06

223 filing records in this dataset, filed from 1995-05-10 to 2020-11-06. Reported financial figures are available; chart coverage varies by period.

Inspect reported changes Compare with another company Historical disclosures Search filings Segments

Watchlist

Latest quarter

Revenue

93.1 million USD

2020 Q3 · USD

Exact inputs and evidence

Revenue: 93106000 USD Source

Operating margin

1.71%

2020 Q3 · %

Exact inputs and evidence

Operating Income: 1595000 USD Source
Revenue: 93106000 USD Source

Operating cash flow

36.7 million USD

2020 Q3 · USD

Exact inputs and evidence

Operating Cash Flow: -6763000 USD Source
Operating Cash Flow: -43442000 USD Source

Free cash flow

36.3 million USD

2020 Q3 · USD

Exact inputs and evidence

Operating Cash Flow: -6763000 USD Source
Operating Cash Flow: -43442000 USD Source
Capital Expenditure: 475000 USD Source
Capital Expenditure: 68000 USD Source

Cash and cash equivalents: 98 million USD 2020-09-30 Source
Exact value

97984000 USD
Long-term debt including current maturities: 289 million USD 2020-09-30 Source
Exact value

289334000 USD
Shares outstanding: 34.5 million shares 2020-09-30 Source
Exact value

34503435 shares

Reported share-count change

1.73% · 588 thousand shares

Year-over-year change in reported shares. Splits, issuance and buybacks can affect this figure; it does not isolate employee compensation or economic dilution.

Exact inputs and evidence

33915509 shares · 2019-09-30· Source
34503435 shares · 2020-09-30· Source

Trailing twelve months

The four most recent complete quarters added together. This gives a full-year view that includes the latest quarterly results.

Net income

-228 million USD

2019-10-01 – 2020-09-30

Exact inputs and evidence

Net income: -200152000 USD · 2019-10-01 – 2019-12-31 Source
Net income: -24491000 USD · 2020-01-01 – 2020-03-31 Source
Net income: -13244000 USD · 2020-04-01 – 2020-06-30 Source
Net income: 9702000 USD · 2020-07-01 – 2020-09-30 Source

Includes later revisions to earlier periods. Annual charts exclude incomplete years.

Latest filing recorded: 2020-11-06.

Financial data available through: 2019-12-31.

Coverage by financial measure

Revenue: 11 of 11 periods available· newest 2019-12-31
Operating income: 6 of 11 periods available· newest 2019-12-31
Net income: 7 of 11 periods available· newest 2019-12-31
Operating cash flow: 11 of 11 periods available· newest 2019-12-31
Capital expenditure: 9 of 11 periods available· newest 2019-12-31
Total assets: 10 of 11 periods available· newest 2019-12-31
Total liabilities: 10 of 11 periods available· newest 2019-12-31
Current assets: 10 of 11 periods available· newest 2019-12-31
Current liabilities: 10 of 11 periods available· newest 2019-12-31
Cash and cash equivalents: 11 of 11 periods available· newest 2019-12-31
Long-term debt including current maturities: 5 of 11 periods available· newest 2019-12-31
Shares outstanding: 10 of 11 periods available· newest 2019-12-31

Coverage describes values retained in this snapshot. Missing values are not zero; loading limits are reported separately.

What changed year over year

Latest complete year compared with the corresponding period one year earlier. These are measured changes; they do not establish their business causes.

Revenue
-30.8%

Prior period

USD 472.05 million

2018-01-01 – 2018-12-31
Current period

USD 326.55 million

2019-01-01 – 2019-12-31

Exact inputs and evidence

326546000 − 472048000 = -145502000 USD

472048000 USD · 2018-01-01 – 2018-12-31
Inspect prior input Prior source
326546000 USD · 2019-01-01 – 2019-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Revenue · AMAG PHARMACEUTICALS, INC. · 2019-12-31 AMAG PHARMACEUTICALS, INC. (edgar:792977) Year-over-year change in Revenue: -145502000 USD Concept: fundies:Revenue Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T11:54:01Z Snapshot: 7ec3776b1086194e1be37aed54cd06568891eaee4d6ff4b3090d5b728b90d4d5 Dimensions: Consolidated View: https://fundies.io/companies/edgar/792977?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:Revenue: 326546000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/792977/000079297720000090/a201910-ka.htm#3174978 Filing: 000079297720000090 Input fundies:Revenue: 472048000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/792977/000079297720000090/a201910-ka.htm#3199683 Filing: 000079297720000090
The citation records this snapshot. The page link may show a newer release later.
Net income
−USD 399.16 million

Prior period

−USD 68.5 million

2018-01-01 – 2018-12-31
Current period

−USD 467.66 million

2019-01-01 – 2019-12-31

Exact inputs and evidence

-467661000 − -68497000 = -399164000 USD

-68497000 USD · 2018-01-01 – 2018-12-31
Inspect prior input Prior source
-467661000 USD · 2019-01-01 – 2019-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Net income · AMAG PHARMACEUTICALS, INC. · 2019-12-31 AMAG PHARMACEUTICALS, INC. (edgar:792977) Year-over-year change in Net income: -399164000 USD Concept: fundies:NetIncome Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T11:54:01Z Snapshot: 7ec3776b1086194e1be37aed54cd06568891eaee4d6ff4b3090d5b728b90d4d5 Dimensions: Consolidated View: https://fundies.io/companies/edgar/792977?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:NetIncome: -467661000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/792977/000079297720000090/a201910-ka.htm#3184701 Filing: 000079297720000090 Input fundies:NetIncome: -68497000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/792977/000079297720000090/a201910-ka.htm#3209296 Filing: 000079297720000090
The citation records this snapshot. The page link may show a newer release later.
Operating cash flow
-306.7%

Prior period

USD 60.8 million

2018-01-01 – 2018-12-31
Current period

−USD 125.7 million

2019-01-01 – 2019-12-31

Exact inputs and evidence

-125696000 − 60800000 = -186496000 USD

60800000 USD · 2018-01-01 – 2018-12-31
Inspect prior input Prior source
-125696000 USD · 2019-01-01 – 2019-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Operating cash flow · AMAG PHARMACEUTICALS, INC. · 2019-12-31 AMAG PHARMACEUTICALS, INC. (edgar:792977) Year-over-year change in Operating cash flow: -186496000 USD Concept: fundies:OperatingCashFlow Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T11:54:01Z Snapshot: 7ec3776b1086194e1be37aed54cd06568891eaee4d6ff4b3090d5b728b90d4d5 Dimensions: Consolidated View: https://fundies.io/companies/edgar/792977?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:OperatingCashFlow: -125696000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/792977/000079297720000090/a201910-ka.htm#1421976 Filing: 000079297720000090 Input fundies:OperatingCashFlow: 60800000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/792977/000079297720000090/a201910-ka.htm#1423006 Filing: 000079297720000090
The citation records this snapshot. The page link may show a newer release later.
Capital expenditure
+0.4%

Prior period

USD 2.53 million

2018-01-01 – 2018-12-31
Current period

USD 2.54 million

2019-01-01 – 2019-12-31

Exact inputs and evidence

2544000 − 2534000 = 10000 USD

2534000 USD · 2018-01-01 – 2018-12-31
Inspect prior input Prior source
2544000 USD · 2019-01-01 – 2019-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Capital expenditure · AMAG PHARMACEUTICALS, INC. · 2019-12-31 AMAG PHARMACEUTICALS, INC. (edgar:792977) Year-over-year change in Capital expenditure: 10000 USD Concept: fundies:CapitalExpenditure Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T11:54:01Z Snapshot: 7ec3776b1086194e1be37aed54cd06568891eaee4d6ff4b3090d5b728b90d4d5 Dimensions: Consolidated View: https://fundies.io/companies/edgar/792977?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:CapitalExpenditure: 2544000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/792977/000079297720000090/a201910-ka.htm#1443170 Filing: 000079297720000090 Input fundies:CapitalExpenditure: 2534000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/792977/000079297720000090/a201910-ka.htm#1444068 Filing: 000079297720000090
The citation records this snapshot. The page link may show a newer release later.

Where revenue goes

How a period’s revenue divides into costs and what remains as profit. Items marked Derived are calculated by subtraction from reported figures.

2019 2019-01-01 – 2019-12-31

Revenue USD 326.55 million 100% of revenue
Operating costs Derived USD 773.26 million 237% of revenue
Operating income −USD 446.71 million −137% of revenue
Tax, interest and other Derived USD 20.95 million 6.4% of revenue
Net income −USD 467.66 million −143% of revenue

Cash

Operating cash flow −USD 125.7 million −38% of revenue
Capital expenditure USD 2.54 million 0.8% of revenue
Free cash flow Derived −USD 128.24 million −39% of revenue

Share of revenue by period

Net income
Tax, interest and other
Operating costs

2010 Not shown: operating income or net income is not reported.
2011 Not shown: operating income or net income is not reported.
2012 Not shown: operating income or net income is not reported.
2013 Not shown: operating income or net income is not reported.
2014 Not shown: operating income or net income is not reported.
2015 19%73%
2016 Net loss: net income was −0.6% of revenue.
2017 Operating loss: operating costs were 162% of revenue.
2018 Operating loss: operating costs were 110% of revenue.
2019 Operating loss: operating costs were 237% of revenue.

Values and sources

Revenue breakdown by annual reporting period
Period	Revenue	Operating costs	Operating income	Tax, interest and other	Net income	Free cash flow	Source
2010 2010-01-01 – 2010-12-31	66245000	Unavailable	Unavailable	Unavailable	-81153000	-2750000 Derived	Source 2010-01-01 – 2010-12-31: 66245000 USD Inspect Revenue Open source 2010-01-01 – 2010-12-31: -81153000 USD Inspect Net Income Open source 2010-01-01 – 2010-12-31: -1527000 USD Inspect Operating Cash Flow Open source 2010-01-01 – 2010-12-31: 1223000 USD Inspect Capital Expenditure Open source
2011 2011-01-01 – 2011-12-31	61249000	Unavailable	Unavailable	Unavailable	Unavailable	-64311000 Derived	Source 2011-01-01 – 2011-12-31: 61249000 USD Inspect Revenue Open source 2011-01-01 – 2011-12-31: -63804000 USD Inspect Operating Cash Flow Open source 2011-01-01 – 2011-12-31: 507000 USD Inspect Capital Expenditure Open source
2012 2012-01-01 – 2012-12-31	85378000	Unavailable	Unavailable	Unavailable	Unavailable	-1204000 Derived	Source 2012-01-01 – 2012-12-31: 85378000 USD Inspect Revenue Open source 2012-01-01 – 2012-12-31: -1157000 USD Inspect Operating Cash Flow Open source 2012-01-01 – 2012-12-31: 47000 USD Inspect Capital Expenditure Open source
2013 2013-01-01 – 2013-12-31	80856000	Unavailable	Unavailable	Unavailable	Unavailable	-8406000 Derived	Source 2013-01-01 – 2013-12-31: 80856000 USD Inspect Revenue Open source 2013-01-01 – 2013-12-31: -6774000 USD Inspect Operating Cash Flow Open source 2013-01-01 – 2013-12-31: 1632000 USD Inspect Capital Expenditure Open source
2014 2014-01-01 – 2014-12-31	124384000	128221000 Derived	-3837000	Unavailable	Unavailable	Unavailable	Source 2014-01-01 – 2014-12-31: 124384000 USD Inspect Revenue Open source 2014-01-01 – 2014-12-31: -3837000 USD Inspect Operating Income Open source 2014-01-01 – 2014-12-31: 11414000 USD Inspect Operating Cash Flow Open source
2015 2015-01-01 – 2015-12-31	418276000	307056000 Derived	111220000	78441000 Derived	32779000	Unavailable	Source 2015-01-01 – 2015-12-31: 418276000 USD Inspect Revenue Open source 2015-01-01 – 2015-12-31: 111220000 USD Inspect Operating Income Open source 2015-01-01 – 2015-12-31: 32779000 USD Inspect Net Income Open source 2015-01-01 – 2015-12-31: 95981000 USD Inspect Operating Cash Flow Open source
2016 2016-01-01 – 2016-12-31	432487000	347408000 Derived	85079000	87562000 Derived	-2483000	240762000 Derived	Source 2016-01-01 – 2016-12-31: 432487000 USD Inspect Revenue Open source 2016-01-01 – 2016-12-31: 85079000 USD Inspect Operating Income Open source 2016-01-01 – 2016-12-31: -2483000 USD Inspect Net Income Open source 2016-01-01 – 2016-12-31: 246222000 USD Inspect Operating Cash Flow Open source 2016-01-01 – 2016-12-31: 5460000 USD Inspect Capital Expenditure Open source
2017 2017-01-01 – 2017-12-31	493967000	799608000 Derived	-305641000	-104878000 Derived	-200763000	97608000 Derived	Source 2017-01-01 – 2017-12-31: 493967000 USD Inspect Revenue Open source 2017-01-01 – 2017-12-31: -305641000 USD Inspect Operating Income Open source 2017-01-01 – 2017-12-31: -200763000 USD Inspect Net Income Open source 2017-01-01 – 2017-12-31: 106596000 USD Inspect Operating Cash Flow Open source 2017-01-01 – 2017-12-31: 8988000 USD Inspect Capital Expenditure Open source
2018 2018-01-01 – 2018-12-31	472048000	521048000 Derived	-49000000	19497000 Derived	-68497000	58266000 Derived	Source 2018-01-01 – 2018-12-31: 472048000 USD Inspect Revenue Open source 2018-01-01 – 2018-12-31: -49000000 USD Inspect Operating Income Open source 2018-01-01 – 2018-12-31: -68497000 USD Inspect Net Income Open source 2018-01-01 – 2018-12-31: 60800000 USD Inspect Operating Cash Flow Open source 2018-01-01 – 2018-12-31: 2534000 USD Inspect Capital Expenditure Open source
2019 2019-01-01 – 2019-12-31	326546000	773258000 Derived	-446712000	20949000 Derived	-467661000	-128240000 Derived	Source 2019-01-01 – 2019-12-31: 326546000 USD Inspect Revenue Open source 2019-01-01 – 2019-12-31: -446712000 USD Inspect Operating Income Open source 2019-01-01 – 2019-12-31: -467661000 USD Inspect Net Income Open source 2019-01-01 – 2019-12-31: -125696000 USD Inspect Operating Cash Flow Open source 2019-01-01 – 2019-12-31: 2544000 USD Inspect Capital Expenditure Open source

Amounts are exact, in USD.

Growth

Sales over time and how quickly they are changing.

Revenue

Revenue reported for each complete financial period.

USD 326.5M 2019

Values and sources

Revenue values and source evidence
Period	Series	Value(USD)	Source evidence
20102010-12-31	Revenue	66245000	Revenue: 66245000 Open source
20112011-12-31	Revenue	61249000	Revenue: 61249000 Open source
20122012-12-31	Revenue	85378000	Revenue: 85378000 Open source
20132013-12-31	Revenue	80856000	Revenue: 80856000 Open source
20142014-12-31	Revenue	124384000	Revenue: 124384000 Open source
20152015-12-31	Revenue	418276000	Revenue: 418276000 Open source
20162016-12-31	Revenue	432487000	Revenue: 432487000 Open source
20172017-12-31	Revenue	493967000	Revenue: 493967000 Open source
20182018-12-31	Revenue	472048000	Revenue: 472048000 Open source
20192019-12-31	Revenue	326546000	Revenue: 326546000 Open source

Revenue growth

Change in revenue from the same financial period one year earlier.

-30.8% 2019

Values and sources

Revenue growth values and source evidence
Period	Series	Value	Source evidence
20102010-12-31	Year over year	285.6%	Revenue: 66245000 Open source Revenue: 17178000 Open source
20112011-12-31	Year over year	-7.5%	Revenue: 61249000 Open source Revenue: 66245000 Open source
20122012-12-31	Year over year	39.4%	Revenue: 85378000 Open source Revenue: 61249000 Open source
20132013-12-31	Year over year	-5.3%	Revenue: 80856000 Open source Revenue: 85378000 Open source
20142014-12-31	Year over year	53.8%	Revenue: 124384000 Open source Revenue: 80856000 Open source
20152015-12-31	Year over year	236.3%	Revenue: 418276000 Open source Revenue: 124384000 Open source
20162016-12-31	Year over year	3.4%	Revenue: 432487000 Open source Revenue: 418276000 Open source
20172017-12-31	Year over year	14.2%	Revenue: 493967000 Open source Revenue: 432487000 Open source
20182018-12-31	Year over year	-4.4%	Revenue: 472048000 Open source Revenue: 493967000 Open source
20192019-12-31	Year over year	-30.8%	Revenue: 326546000 Open source Revenue: 472048000 Open source

Profit and cash

How much revenue becomes profit, and how much cash operations generate.

Profit margins

Operating income, net income and free cash flow as a share of revenue.

Operating margin -136.8% 2019

Net margin -143.2% 2019

Free cash flow margin -39.3% 2019

Operating margin
Net margin
Free cash flow margin

Values and sources

Profit margins values and source evidence
Period	Series	Value	Source evidence
2010-12-31	Operating margin	Not reported	Revenue: 66245000 Open source
2011-12-31	Operating margin	Not reported	Revenue: 61249000 Open source
2012-12-31	Operating margin	Not reported	Revenue: 85378000 Open source
2013-12-31	Operating margin	Not reported	Revenue: 80856000 Open source
20142014-12-31	Operating margin	-3.1%	Operating Income: -3837000 Open source Revenue: 124384000 Open source
20152015-12-31	Operating margin	26.6%	Operating Income: 111220000 Open source Revenue: 418276000 Open source
20162016-12-31	Operating margin	19.7%	Operating Income: 85079000 Open source Revenue: 432487000 Open source
20172017-12-31	Operating margin	-61.9%	Operating Income: -305641000 Open source Revenue: 493967000 Open source
20182018-12-31	Operating margin	-10.4%	Operating Income: -49000000 Open source Revenue: 472048000 Open source
20192019-12-31	Operating margin	-136.8%	Operating Income: -446712000 Open source Revenue: 326546000 Open source
20102010-12-31	Net margin	-122.5%	Net Income: -81153000 Open source Revenue: 66245000 Open source
2011-12-31	Net margin	Not reported	Revenue: 61249000 Open source
2012-12-31	Net margin	Not reported	Revenue: 85378000 Open source
2013-12-31	Net margin	Not reported	Revenue: 80856000 Open source
2014-12-31	Net margin	Not reported	Revenue: 124384000 Open source
20152015-12-31	Net margin	7.8%	Net Income: 32779000 Open source Revenue: 418276000 Open source
20162016-12-31	Net margin	-0.6%	Net Income: -2483000 Open source Revenue: 432487000 Open source
20172017-12-31	Net margin	-40.6%	Net Income: -200763000 Open source Revenue: 493967000 Open source
20182018-12-31	Net margin	-14.5%	Net Income: -68497000 Open source Revenue: 472048000 Open source
20192019-12-31	Net margin	-143.2%	Net Income: -467661000 Open source Revenue: 326546000 Open source
20102010-12-31	Free cash flow margin	-4.2%	Revenue: 66245000 Open source Operating Cash Flow: -1527000 Open source Capital Expenditure: 1223000 Open source
20112011-12-31	Free cash flow margin	-105%	Revenue: 61249000 Open source Operating Cash Flow: -63804000 Open source Capital Expenditure: 507000 Open source
20122012-12-31	Free cash flow margin	-1.4%	Revenue: 85378000 Open source Operating Cash Flow: -1157000 Open source Capital Expenditure: 47000 Open source
20132013-12-31	Free cash flow margin	-10.4%	Revenue: 80856000 Open source Operating Cash Flow: -6774000 Open source Capital Expenditure: 1632000 Open source
20142014-12-31	Free cash flow margin	Not reported	Revenue: 124384000 Open source Operating Cash Flow: 11414000 Open source
20152015-12-31	Free cash flow margin	Not reported	Revenue: 418276000 Open source Operating Cash Flow: 95981000 Open source
20162016-12-31	Free cash flow margin	55.7%	Revenue: 432487000 Open source Operating Cash Flow: 246222000 Open source Capital Expenditure: 5460000 Open source
20172017-12-31	Free cash flow margin	19.8%	Revenue: 493967000 Open source Operating Cash Flow: 106596000 Open source Capital Expenditure: 8988000 Open source
20182018-12-31	Free cash flow margin	12.3%	Revenue: 472048000 Open source Operating Cash Flow: 60800000 Open source Capital Expenditure: 2534000 Open source
20192019-12-31	Free cash flow margin	-39.3%	Revenue: 326546000 Open source Operating Cash Flow: -125696000 Open source Capital Expenditure: 2544000 Open source

Operating cash flow

Cash generated by the company’s normal business operations.

USD -125.7M 2019

Values and sources

Operating cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20102010-12-31	Operating cash flow	-1527000	Operating Cash Flow: -1527000 Open source
20112011-12-31	Operating cash flow	-63804000	Operating Cash Flow: -63804000 Open source
20122012-12-31	Operating cash flow	-1157000	Operating Cash Flow: -1157000 Open source
20132013-12-31	Operating cash flow	-6774000	Operating Cash Flow: -6774000 Open source
20142014-12-31	Operating cash flow	11414000	Operating Cash Flow: 11414000 Open source
20152015-12-31	Operating cash flow	95981000	Operating Cash Flow: 95981000 Open source
20162016-12-31	Operating cash flow	246222000	Operating Cash Flow: 246222000 Open source
20172017-12-31	Operating cash flow	106596000	Operating Cash Flow: 106596000 Open source
20182018-12-31	Operating cash flow	60800000	Operating Cash Flow: 60800000 Open source
20192019-12-31	Operating cash flow	-125696000	Operating Cash Flow: -125696000 Open source

Free cash flow

Operating cash flow minus capital expenditure for the same period and unit.

USD -128.2M 2019

Values and sources

Free cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20102010-12-31	Free cash flow	-2750000	Operating Cash Flow: -1527000 Open source Capital Expenditure: 1223000 Open source
20112011-12-31	Free cash flow	-64311000	Operating Cash Flow: -63804000 Open source Capital Expenditure: 507000 Open source
20122012-12-31	Free cash flow	-1204000	Operating Cash Flow: -1157000 Open source Capital Expenditure: 47000 Open source
20132013-12-31	Free cash flow	-8406000	Operating Cash Flow: -6774000 Open source Capital Expenditure: 1632000 Open source
20142014-12-31	Free cash flow	Unavailable	Operating Cash Flow: 11414000 Open source
20152015-12-31	Free cash flow	Unavailable	Operating Cash Flow: 95981000 Open source
20162016-12-31	Free cash flow	240762000	Operating Cash Flow: 246222000 Open source Capital Expenditure: 5460000 Open source
20172017-12-31	Free cash flow	97608000	Operating Cash Flow: 106596000 Open source Capital Expenditure: 8988000 Open source
20182018-12-31	Free cash flow	58266000	Operating Cash Flow: 60800000 Open source Capital Expenditure: 2534000 Open source
20192019-12-31	Free cash flow	-128240000	Operating Cash Flow: -125696000 Open source Capital Expenditure: 2544000 Open source

Balance sheet

Liabilities and short-term ability to meet obligations at each period end.

Liabilities to assets

Total liabilities as a share of total assets.

64.6% 2019

Values and sources

Liabilities to assets values and source evidence
Period	Series	Value	Source evidence
20102010-12-31	Liabilities / assets	27%	Total Liabilities: 90790000 Open source Total Assets: 336076000 Open source
20112011-12-31	Liabilities / assets	32.4%	Total Liabilities: 86628000 Open source Total Assets: 267224000 Open source
20122012-12-31	Liabilities / assets	33.1%	Total Liabilities: 85340000 Open source Total Assets: 258137000 Open source
20132013-12-31	Liabilities / assets	35.1%	Total Liabilities: 93051000 Open source Total Assets: 265459000 Open source
2014-12-31	Liabilities / assets	Not reported	No source recorded
20152015-12-31	Liabilities / assets	62.4%	Total Liabilities: 1543946000 Open source Total Assets: 2476210000 Open source
20162016-12-31	Liabilities / assets	62.3%	Total Liabilities: 1544037000 Open source Total Assets: 2478426000 Open source
20172017-12-31	Liabilities / assets	58.4%	Total Liabilities: 1110112000 Open source Total Assets: 1900356000 Open source
20182018-12-31	Liabilities / assets	36.9%	Total Liabilities: 433902000 Open source Total Assets: 1175459000 Open source
20192019-12-31	Liabilities / assets	64.6%	Total Liabilities: 511411000 Open source Total Assets: 791227000 Open source

Current assets to current liabilities

Current assets divided by current liabilities.

1.48× 2019

Values and sources

Current assets to current liabilities values and source evidence
Period	Series	Value	Source evidence
20102010-12-31	Current assets / current liabilities	7.92×	Current Assets: 290784000 Open source Current Liabilities: 36711000 Open source
20112011-12-31	Current assets / current liabilities	6.16×	Current Assets: 240031000 Open source Current Liabilities: 38994000 Open source
20122012-12-31	Current assets / current liabilities	7.72×	Current Assets: 254380000 Open source Current Liabilities: 32957000 Open source
20132013-12-31	Current assets / current liabilities	7.38×	Current Assets: 244405000 Open source Current Liabilities: 33121000 Open source
2014-12-31	Current assets / current liabilities	Not reported	No source recorded
20152015-12-31	Current assets / current liabilities	2.47×	Current Assets: 606674000 Open source Current Liabilities: 245921000 Open source
20162016-12-31	Current assets / current liabilities	2.3×	Current Assets: 718558000 Open source Current Liabilities: 312877000 Open source
20172017-12-31	Current assets / current liabilities	1.74×	Current Assets: 481868000 Open source Current Liabilities: 277718000 Open source
20182018-12-31	Current assets / current liabilities	3.08×	Current Assets: 525170000 Open source Current Liabilities: 170542000 Open source
20192019-12-31	Current assets / current liabilities	1.48×	Current Assets: 316567000 Open source Current Liabilities: 214497000 Open source

Cash generation

Compare reported profit with operating cash and capital spending. Free cash flow is calculated as operating cash flow minus capital expenditure when both exact, consolidated amounts match the same period and unit.

Cash generation by annual reporting period
Period	Net income	Operating cash flow	Capital expenditure	Free cash flow
2010 2010-01-01 – 2010-12-31	−USD 81.15 million Exact value Exact value: -81153000 USD 2010-01-01 – 2010-12-31: -81153000 USD Inspect Net Income Open source Share or cite Citation for Net Income · AMAG PHARMACEUTICALS, INC. · 2010-12-31 AMAG PHARMACEUTICALS, INC. (edgar:792977) Net Income: -81153000 USD Concept: fundies:NetIncome Period: 2010-01-01 to 2010-12-31 Values: Latest reported Published: 2026-11-02T11:54:01Z Snapshot: 7ec3776b1086194e1be37aed54cd06568891eaee4d6ff4b3090d5b728b90d4d5 Dimensions: Consolidated View: https://fundies.io/companies/edgar/792977/explain?concept=fundies%3ANetIncome&period=2010-12-31&surface=latest&period_type=duration&start=2010-01-01&unit=USD&dimensions= Input fundies:NetIncome: -81153000 USD (2010-01-01 to 2010-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/792977/0001047469-11-001351.txt#11603 The citation records this snapshot. The page link may show a newer release later.	−USD 1.53 million Exact value Exact value: -1527000 USD 2010-01-01 – 2010-12-31: -1527000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · AMAG PHARMACEUTICALS, INC. · 2010-12-31 AMAG PHARMACEUTICALS, INC. (edgar:792977) Operating Cash Flow: -1527000 USD Concept: fundies:OperatingCashFlow Period: 2010-01-01 to 2010-12-31 Values: Latest reported Published: 2026-11-02T11:54:01Z Snapshot: 7ec3776b1086194e1be37aed54cd06568891eaee4d6ff4b3090d5b728b90d4d5 Dimensions: Consolidated View: https://fundies.io/companies/edgar/792977/explain?concept=fundies%3AOperatingCashFlow&period=2010-12-31&surface=latest&period_type=duration&start=2010-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -1527000 USD (2010-01-01 to 2010-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/792977/000104746913002092/amag-20121231.xml#740277 Filing: 000104746913002092 The citation records this snapshot. The page link may show a newer release later.	USD 1.22 million Exact value Exact value: 1223000 USD 2010-01-01 – 2010-12-31: 1223000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · AMAG PHARMACEUTICALS, INC. · 2010-12-31 AMAG PHARMACEUTICALS, INC. (edgar:792977) Capital Expenditure: 1223000 USD Concept: fundies:CapitalExpenditure Period: 2010-01-01 to 2010-12-31 Values: Latest reported Published: 2026-11-02T11:54:01Z Snapshot: 7ec3776b1086194e1be37aed54cd06568891eaee4d6ff4b3090d5b728b90d4d5 Dimensions: Consolidated View: https://fundies.io/companies/edgar/792977/explain?concept=fundies%3ACapitalExpenditure&period=2010-12-31&surface=latest&period_type=duration&start=2010-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 1223000 USD (2010-01-01 to 2010-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/792977/000104746913002092/amag-20121231.xml#741441 Filing: 000104746913002092 The citation records this snapshot. The page link may show a newer release later.	−USD 2.75 million Calculation and evidence -1527000 − 1223000 USD Exact free cash flow: -2750000 USD 2010-01-01 – 2010-12-31: -1527000 USD · Inspect Operating Cash Flow · Source 2010-01-01 – 2010-12-31: 1223000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · AMAG PHARMACEUTICALS, INC. · 2010-12-31 AMAG PHARMACEUTICALS, INC. (edgar:792977) Free cash flow: -2750000 USD Concept: free-cash-flow Period: 2010-01-01 to 2010-12-31 Values: Latest reported Published: 2026-11-02T11:54:01Z Snapshot: 7ec3776b1086194e1be37aed54cd06568891eaee4d6ff4b3090d5b728b90d4d5 Dimensions: Consolidated View: https://fundies.io/companies/edgar/792977?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -1527000 USD (2010-01-01 to 2010-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/792977/000104746913002092/amag-20121231.xml#740277 Filing: 000104746913002092 Input fundies:CapitalExpenditure: 1223000 USD (2010-01-01 to 2010-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/792977/000104746913002092/amag-20121231.xml#741441 Filing: 000104746913002092 The citation records this snapshot. The page link may show a newer release later.
2011 2011-01-01 – 2011-12-31	Unavailable Not reported for this period.	−USD 63.8 million Exact value Exact value: -63804000 USD 2011-01-01 – 2011-12-31: -63804000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · AMAG PHARMACEUTICALS, INC. · 2011-12-31 AMAG PHARMACEUTICALS, INC. (edgar:792977) Operating Cash Flow: -63804000 USD Concept: fundies:OperatingCashFlow Period: 2011-01-01 to 2011-12-31 Values: Latest reported Published: 2026-11-02T11:54:01Z Snapshot: 7ec3776b1086194e1be37aed54cd06568891eaee4d6ff4b3090d5b728b90d4d5 Dimensions: Consolidated View: https://fundies.io/companies/edgar/792977/explain?concept=fundies%3AOperatingCashFlow&period=2011-12-31&surface=latest&period_type=duration&start=2011-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -63804000 USD (2011-01-01 to 2011-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/792977/000104746914000718/amag-20131231.xml#1573257 Filing: 000104746914000718 The citation records this snapshot. The page link may show a newer release later.	USD 507,000 Exact value Exact value: 507000 USD 2011-01-01 – 2011-12-31: 507000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · AMAG PHARMACEUTICALS, INC. · 2011-12-31 AMAG PHARMACEUTICALS, INC. (edgar:792977) Capital Expenditure: 507000 USD Concept: fundies:CapitalExpenditure Period: 2011-01-01 to 2011-12-31 Values: Latest reported Published: 2026-11-02T11:54:01Z Snapshot: 7ec3776b1086194e1be37aed54cd06568891eaee4d6ff4b3090d5b728b90d4d5 Dimensions: Consolidated View: https://fundies.io/companies/edgar/792977/explain?concept=fundies%3ACapitalExpenditure&period=2011-12-31&surface=latest&period_type=duration&start=2011-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 507000 USD (2011-01-01 to 2011-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/792977/000104746914000718/amag-20131231.xml#1574889 Filing: 000104746914000718 The citation records this snapshot. The page link may show a newer release later.	−USD 64.31 million Calculation and evidence -63804000 − 507000 USD Exact free cash flow: -64311000 USD 2011-01-01 – 2011-12-31: -63804000 USD · Inspect Operating Cash Flow · Source 2011-01-01 – 2011-12-31: 507000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · AMAG PHARMACEUTICALS, INC. · 2011-12-31 AMAG PHARMACEUTICALS, INC. (edgar:792977) Free cash flow: -64311000 USD Concept: free-cash-flow Period: 2011-01-01 to 2011-12-31 Values: Latest reported Published: 2026-11-02T11:54:01Z Snapshot: 7ec3776b1086194e1be37aed54cd06568891eaee4d6ff4b3090d5b728b90d4d5 Dimensions: Consolidated View: https://fundies.io/companies/edgar/792977?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -63804000 USD (2011-01-01 to 2011-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/792977/000104746914000718/amag-20131231.xml#1573257 Filing: 000104746914000718 Input fundies:CapitalExpenditure: 507000 USD (2011-01-01 to 2011-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/792977/000104746914000718/amag-20131231.xml#1574889 Filing: 000104746914000718 The citation records this snapshot. The page link may show a newer release later.
2012 2012-01-01 – 2012-12-31	Unavailable Not reported for this period.	−USD 1.16 million Exact value Exact value: -1157000 USD 2012-01-01 – 2012-12-31: -1157000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · AMAG PHARMACEUTICALS, INC. · 2012-12-31 AMAG PHARMACEUTICALS, INC. (edgar:792977) Operating Cash Flow: -1157000 USD Concept: fundies:OperatingCashFlow Period: 2012-01-01 to 2012-12-31 Values: Latest reported Published: 2026-11-02T11:54:01Z Snapshot: 7ec3776b1086194e1be37aed54cd06568891eaee4d6ff4b3090d5b728b90d4d5 Dimensions: Consolidated View: https://fundies.io/companies/edgar/792977/explain?concept=fundies%3AOperatingCashFlow&period=2012-12-31&surface=latest&period_type=duration&start=2012-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -1157000 USD (2012-01-01 to 2012-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/792977/000104746914000718/amag-20131231.xml#1573042 Filing: 000104746914000718 The citation records this snapshot. The page link may show a newer release later.	USD 47,000 Exact value Exact value: 47000 USD 2012-01-01 – 2012-12-31: 47000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · AMAG PHARMACEUTICALS, INC. · 2012-12-31 AMAG PHARMACEUTICALS, INC. (edgar:792977) Capital Expenditure: 47000 USD Concept: fundies:CapitalExpenditure Period: 2012-01-01 to 2012-12-31 Values: Latest reported Published: 2026-11-02T11:54:01Z Snapshot: 7ec3776b1086194e1be37aed54cd06568891eaee4d6ff4b3090d5b728b90d4d5 Dimensions: Consolidated View: https://fundies.io/companies/edgar/792977/explain?concept=fundies%3ACapitalExpenditure&period=2012-12-31&surface=latest&period_type=duration&start=2012-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 47000 USD (2012-01-01 to 2012-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/792977/000104746914000718/amag-20131231.xml#1574717 Filing: 000104746914000718 The citation records this snapshot. The page link may show a newer release later.	−USD 1.2 million Calculation and evidence -1157000 − 47000 USD Exact free cash flow: -1204000 USD 2012-01-01 – 2012-12-31: -1157000 USD · Inspect Operating Cash Flow · Source 2012-01-01 – 2012-12-31: 47000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · AMAG PHARMACEUTICALS, INC. · 2012-12-31 AMAG PHARMACEUTICALS, INC. (edgar:792977) Free cash flow: -1204000 USD Concept: free-cash-flow Period: 2012-01-01 to 2012-12-31 Values: Latest reported Published: 2026-11-02T11:54:01Z Snapshot: 7ec3776b1086194e1be37aed54cd06568891eaee4d6ff4b3090d5b728b90d4d5 Dimensions: Consolidated View: https://fundies.io/companies/edgar/792977?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -1157000 USD (2012-01-01 to 2012-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/792977/000104746914000718/amag-20131231.xml#1573042 Filing: 000104746914000718 Input fundies:CapitalExpenditure: 47000 USD (2012-01-01 to 2012-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/792977/000104746914000718/amag-20131231.xml#1574717 Filing: 000104746914000718 The citation records this snapshot. The page link may show a newer release later.
2013 2013-01-01 – 2013-12-31	Unavailable Not reported for this period.	−USD 6.77 million Exact value Exact value: -6774000 USD 2013-01-01 – 2013-12-31: -6774000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · AMAG PHARMACEUTICALS, INC. · 2013-12-31 AMAG PHARMACEUTICALS, INC. (edgar:792977) Operating Cash Flow: -6774000 USD Concept: fundies:OperatingCashFlow Period: 2013-01-01 to 2013-12-31 Values: Latest reported Published: 2026-11-02T11:54:01Z Snapshot: 7ec3776b1086194e1be37aed54cd06568891eaee4d6ff4b3090d5b728b90d4d5 Dimensions: Consolidated View: https://fundies.io/companies/edgar/792977/explain?concept=fundies%3AOperatingCashFlow&period=2013-12-31&surface=latest&period_type=duration&start=2013-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -6774000 USD (2013-01-01 to 2013-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/792977/000104746914000718/amag-20131231.xml#1716653 Filing: 000104746914000718 The citation records this snapshot. The page link may show a newer release later.	USD 1.63 million Exact value Exact value: 1632000 USD 2013-01-01 – 2013-12-31: 1632000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · AMAG PHARMACEUTICALS, INC. · 2013-12-31 AMAG PHARMACEUTICALS, INC. (edgar:792977) Capital Expenditure: 1632000 USD Concept: fundies:CapitalExpenditure Period: 2013-01-01 to 2013-12-31 Values: Latest reported Published: 2026-11-02T11:54:01Z Snapshot: 7ec3776b1086194e1be37aed54cd06568891eaee4d6ff4b3090d5b728b90d4d5 Dimensions: Consolidated View: https://fundies.io/companies/edgar/792977/explain?concept=fundies%3ACapitalExpenditure&period=2013-12-31&surface=latest&period_type=duration&start=2013-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 1632000 USD (2013-01-01 to 2013-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/792977/000104746914000718/amag-20131231.xml#1717256 Filing: 000104746914000718 The citation records this snapshot. The page link may show a newer release later.	−USD 8.41 million Calculation and evidence -6774000 − 1632000 USD Exact free cash flow: -8406000 USD 2013-01-01 – 2013-12-31: -6774000 USD · Inspect Operating Cash Flow · Source 2013-01-01 – 2013-12-31: 1632000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · AMAG PHARMACEUTICALS, INC. · 2013-12-31 AMAG PHARMACEUTICALS, INC. (edgar:792977) Free cash flow: -8406000 USD Concept: free-cash-flow Period: 2013-01-01 to 2013-12-31 Values: Latest reported Published: 2026-11-02T11:54:01Z Snapshot: 7ec3776b1086194e1be37aed54cd06568891eaee4d6ff4b3090d5b728b90d4d5 Dimensions: Consolidated View: https://fundies.io/companies/edgar/792977?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -6774000 USD (2013-01-01 to 2013-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/792977/000104746914000718/amag-20131231.xml#1716653 Filing: 000104746914000718 Input fundies:CapitalExpenditure: 1632000 USD (2013-01-01 to 2013-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/792977/000104746914000718/amag-20131231.xml#1717256 Filing: 000104746914000718 The citation records this snapshot. The page link may show a newer release later.
2014 2014-01-01 – 2014-12-31	Unavailable Not reported for this period.	USD 11.41 million Exact value Exact value: 11414000 USD 2014-01-01 – 2014-12-31: 11414000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · AMAG PHARMACEUTICALS, INC. · 2014-12-31 AMAG PHARMACEUTICALS, INC. (edgar:792977) Operating Cash Flow: 11414000 USD Concept: fundies:OperatingCashFlow Period: 2014-01-01 to 2014-12-31 Values: Latest reported Published: 2026-11-02T11:54:01Z Snapshot: 7ec3776b1086194e1be37aed54cd06568891eaee4d6ff4b3090d5b728b90d4d5 Dimensions: Consolidated View: https://fundies.io/companies/edgar/792977/explain?concept=fundies%3AOperatingCashFlow&period=2014-12-31&surface=latest&period_type=duration&start=2014-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: 11414000 USD (2014-01-01 to 2014-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/792977/000079297717000007/amag-20161231.xml#536858 Filing: 000079297717000007 The citation records this snapshot. The page link may show a newer release later.	Unavailable Not reported for this period.	Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period.
2015 2015-01-01 – 2015-12-31	USD 32.78 million Exact value Exact value: 32779000 USD 2015-01-01 – 2015-12-31: 32779000 USD Inspect Net Income Open source Share or cite Citation for Net Income · AMAG PHARMACEUTICALS, INC. · 2015-12-31 AMAG PHARMACEUTICALS, INC. (edgar:792977) Net Income: 32779000 USD Concept: fundies:NetIncome Period: 2015-01-01 to 2015-12-31 Values: Latest reported Published: 2026-11-02T11:54:01Z Snapshot: 7ec3776b1086194e1be37aed54cd06568891eaee4d6ff4b3090d5b728b90d4d5 Dimensions: Consolidated View: https://fundies.io/companies/edgar/792977/explain?concept=fundies%3ANetIncome&period=2015-12-31&surface=latest&period_type=duration&start=2015-01-01&unit=USD&dimensions= Input fundies:NetIncome: 32779000 USD (2015-01-01 to 2015-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/792977/000079297718000012/amag-20171231.xml#526978 Filing: 000079297718000012 The citation records this snapshot. The page link may show a newer release later.	USD 95.98 million Exact value Exact value: 95981000 USD 2015-01-01 – 2015-12-31: 95981000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · AMAG PHARMACEUTICALS, INC. · 2015-12-31 AMAG PHARMACEUTICALS, INC. (edgar:792977) Operating Cash Flow: 95981000 USD Concept: fundies:OperatingCashFlow Period: 2015-01-01 to 2015-12-31 Values: Latest reported Published: 2026-11-02T11:54:01Z Snapshot: 7ec3776b1086194e1be37aed54cd06568891eaee4d6ff4b3090d5b728b90d4d5 Dimensions: Consolidated View: https://fundies.io/companies/edgar/792977/explain?concept=fundies%3AOperatingCashFlow&period=2015-12-31&surface=latest&period_type=duration&start=2015-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: 95981000 USD (2015-01-01 to 2015-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/792977/000079297718000012/amag-20171231.xml#526343 Filing: 000079297718000012 The citation records this snapshot. The page link may show a newer release later.	Unavailable Not reported for this period.	Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period.
2016 2016-01-01 – 2016-12-31	−USD 2.48 million Exact value Exact value: -2483000 USD 2016-01-01 – 2016-12-31: -2483000 USD Inspect Net Income Open source Share or cite Citation for Net Income · AMAG PHARMACEUTICALS, INC. · 2016-12-31 AMAG PHARMACEUTICALS, INC. (edgar:792977) Net Income: -2483000 USD Concept: fundies:NetIncome Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T11:54:01Z Snapshot: 7ec3776b1086194e1be37aed54cd06568891eaee4d6ff4b3090d5b728b90d4d5 Dimensions: Consolidated View: https://fundies.io/companies/edgar/792977/explain?concept=fundies%3ANetIncome&period=2016-12-31&surface=latest&period_type=duration&start=2016-01-01&unit=USD&dimensions= Input fundies:NetIncome: -2483000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/792977/000079297719000036/amag-20181231.xml#593728 Filing: 000079297719000036 The citation records this snapshot. The page link may show a newer release later.	USD 246.22 million Exact value Exact value: 246222000 USD 2016-01-01 – 2016-12-31: 246222000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · AMAG PHARMACEUTICALS, INC. · 2016-12-31 AMAG PHARMACEUTICALS, INC. (edgar:792977) Operating Cash Flow: 246222000 USD Concept: fundies:OperatingCashFlow Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T11:54:01Z Snapshot: 7ec3776b1086194e1be37aed54cd06568891eaee4d6ff4b3090d5b728b90d4d5 Dimensions: Consolidated View: https://fundies.io/companies/edgar/792977/explain?concept=fundies%3AOperatingCashFlow&period=2016-12-31&surface=latest&period_type=duration&start=2016-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: 246222000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/792977/000079297719000036/amag-20181231.xml#593093 Filing: 000079297719000036 The citation records this snapshot. The page link may show a newer release later.	USD 5.46 million Exact value Exact value: 5460000 USD 2016-01-01 – 2016-12-31: 5460000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · AMAG PHARMACEUTICALS, INC. · 2016-12-31 AMAG PHARMACEUTICALS, INC. (edgar:792977) Capital Expenditure: 5460000 USD Concept: fundies:CapitalExpenditure Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T11:54:01Z Snapshot: 7ec3776b1086194e1be37aed54cd06568891eaee4d6ff4b3090d5b728b90d4d5 Dimensions: Consolidated View: https://fundies.io/companies/edgar/792977/explain?concept=fundies%3ACapitalExpenditure&period=2016-12-31&surface=latest&period_type=duration&start=2016-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 5460000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/792977/000079297719000036/amag-20181231.xml#620067 Filing: 000079297719000036 The citation records this snapshot. The page link may show a newer release later.	USD 240.76 million Calculation and evidence 246222000 − 5460000 USD Exact free cash flow: 240762000 USD 2016-01-01 – 2016-12-31: 246222000 USD · Inspect Operating Cash Flow · Source 2016-01-01 – 2016-12-31: 5460000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · AMAG PHARMACEUTICALS, INC. · 2016-12-31 AMAG PHARMACEUTICALS, INC. (edgar:792977) Free cash flow: 240762000 USD Concept: free-cash-flow Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T11:54:01Z Snapshot: 7ec3776b1086194e1be37aed54cd06568891eaee4d6ff4b3090d5b728b90d4d5 Dimensions: Consolidated View: https://fundies.io/companies/edgar/792977?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: 246222000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/792977/000079297719000036/amag-20181231.xml#593093 Filing: 000079297719000036 Input fundies:CapitalExpenditure: 5460000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/792977/000079297719000036/amag-20181231.xml#620067 Filing: 000079297719000036 The citation records this snapshot. The page link may show a newer release later.
2017 2017-01-01 – 2017-12-31	−USD 200.76 million Exact value Exact value: -200763000 USD 2017-01-01 – 2017-12-31: -200763000 USD Inspect Net Income Open source Share or cite Citation for Net Income · AMAG PHARMACEUTICALS, INC. · 2017-12-31 AMAG PHARMACEUTICALS, INC. (edgar:792977) Net Income: -200763000 USD Concept: fundies:NetIncome Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T11:54:01Z Snapshot: 7ec3776b1086194e1be37aed54cd06568891eaee4d6ff4b3090d5b728b90d4d5 Dimensions: Consolidated View: https://fundies.io/companies/edgar/792977/explain?concept=fundies%3ANetIncome&period=2017-12-31&surface=latest&period_type=duration&start=2017-01-01&unit=USD&dimensions= Input fundies:NetIncome: -200763000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/792977/000079297720000090/a201910-ka.htm#3234068 Filing: 000079297720000090 The citation records this snapshot. The page link may show a newer release later.	USD 106.6 million Exact value Exact value: 106596000 USD 2017-01-01 – 2017-12-31: 106596000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · AMAG PHARMACEUTICALS, INC. · 2017-12-31 AMAG PHARMACEUTICALS, INC. (edgar:792977) Operating Cash Flow: 106596000 USD Concept: fundies:OperatingCashFlow Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T11:54:01Z Snapshot: 7ec3776b1086194e1be37aed54cd06568891eaee4d6ff4b3090d5b728b90d4d5 Dimensions: Consolidated View: https://fundies.io/companies/edgar/792977/explain?concept=fundies%3AOperatingCashFlow&period=2017-12-31&surface=latest&period_type=duration&start=2017-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: 106596000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/792977/000079297720000090/a201910-ka.htm#1423977 Filing: 000079297720000090 The citation records this snapshot. The page link may show a newer release later.	USD 8.99 million Exact value Exact value: 8988000 USD 2017-01-01 – 2017-12-31: 8988000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · AMAG PHARMACEUTICALS, INC. · 2017-12-31 AMAG PHARMACEUTICALS, INC. (edgar:792977) Capital Expenditure: 8988000 USD Concept: fundies:CapitalExpenditure Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T11:54:01Z Snapshot: 7ec3776b1086194e1be37aed54cd06568891eaee4d6ff4b3090d5b728b90d4d5 Dimensions: Consolidated View: https://fundies.io/companies/edgar/792977/explain?concept=fundies%3ACapitalExpenditure&period=2017-12-31&surface=latest&period_type=duration&start=2017-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 8988000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/792977/000079297720000090/a201910-ka.htm#1444966 Filing: 000079297720000090 The citation records this snapshot. The page link may show a newer release later.	USD 97.61 million Calculation and evidence 106596000 − 8988000 USD Exact free cash flow: 97608000 USD 2017-01-01 – 2017-12-31: 106596000 USD · Inspect Operating Cash Flow · Source 2017-01-01 – 2017-12-31: 8988000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · AMAG PHARMACEUTICALS, INC. · 2017-12-31 AMAG PHARMACEUTICALS, INC. (edgar:792977) Free cash flow: 97608000 USD Concept: free-cash-flow Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T11:54:01Z Snapshot: 7ec3776b1086194e1be37aed54cd06568891eaee4d6ff4b3090d5b728b90d4d5 Dimensions: Consolidated View: https://fundies.io/companies/edgar/792977?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: 106596000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/792977/000079297720000090/a201910-ka.htm#1423977 Filing: 000079297720000090 Input fundies:CapitalExpenditure: 8988000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/792977/000079297720000090/a201910-ka.htm#1444966 Filing: 000079297720000090 The citation records this snapshot. The page link may show a newer release later.
2018 2018-01-01 – 2018-12-31	−USD 68.5 million Exact value Exact value: -68497000 USD 2018-01-01 – 2018-12-31: -68497000 USD Inspect Net Income Open source Share or cite Citation for Net Income · AMAG PHARMACEUTICALS, INC. · 2018-12-31 AMAG PHARMACEUTICALS, INC. (edgar:792977) Net Income: -68497000 USD Concept: fundies:NetIncome Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T11:54:01Z Snapshot: 7ec3776b1086194e1be37aed54cd06568891eaee4d6ff4b3090d5b728b90d4d5 Dimensions: Consolidated View: https://fundies.io/companies/edgar/792977/explain?concept=fundies%3ANetIncome&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:NetIncome: -68497000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/792977/000079297720000090/a201910-ka.htm#3209296 Filing: 000079297720000090 The citation records this snapshot. The page link may show a newer release later.	USD 60.8 million Exact value Exact value: 60800000 USD 2018-01-01 – 2018-12-31: 60800000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · AMAG PHARMACEUTICALS, INC. · 2018-12-31 AMAG PHARMACEUTICALS, INC. (edgar:792977) Operating Cash Flow: 60800000 USD Concept: fundies:OperatingCashFlow Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T11:54:01Z Snapshot: 7ec3776b1086194e1be37aed54cd06568891eaee4d6ff4b3090d5b728b90d4d5 Dimensions: Consolidated View: https://fundies.io/companies/edgar/792977/explain?concept=fundies%3AOperatingCashFlow&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: 60800000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/792977/000079297720000090/a201910-ka.htm#1423006 Filing: 000079297720000090 The citation records this snapshot. The page link may show a newer release later.	USD 2.53 million Exact value Exact value: 2534000 USD 2018-01-01 – 2018-12-31: 2534000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · AMAG PHARMACEUTICALS, INC. · 2018-12-31 AMAG PHARMACEUTICALS, INC. (edgar:792977) Capital Expenditure: 2534000 USD Concept: fundies:CapitalExpenditure Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T11:54:01Z Snapshot: 7ec3776b1086194e1be37aed54cd06568891eaee4d6ff4b3090d5b728b90d4d5 Dimensions: Consolidated View: https://fundies.io/companies/edgar/792977/explain?concept=fundies%3ACapitalExpenditure&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 2534000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/792977/000079297720000090/a201910-ka.htm#1444068 Filing: 000079297720000090 The citation records this snapshot. The page link may show a newer release later.	USD 58.27 million Calculation and evidence 60800000 − 2534000 USD Exact free cash flow: 58266000 USD 2018-01-01 – 2018-12-31: 60800000 USD · Inspect Operating Cash Flow · Source 2018-01-01 – 2018-12-31: 2534000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · AMAG PHARMACEUTICALS, INC. · 2018-12-31 AMAG PHARMACEUTICALS, INC. (edgar:792977) Free cash flow: 58266000 USD Concept: free-cash-flow Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T11:54:01Z Snapshot: 7ec3776b1086194e1be37aed54cd06568891eaee4d6ff4b3090d5b728b90d4d5 Dimensions: Consolidated View: https://fundies.io/companies/edgar/792977?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: 60800000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/792977/000079297720000090/a201910-ka.htm#1423006 Filing: 000079297720000090 Input fundies:CapitalExpenditure: 2534000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/792977/000079297720000090/a201910-ka.htm#1444068 Filing: 000079297720000090 The citation records this snapshot. The page link may show a newer release later.
2019 2019-01-01 – 2019-12-31	−USD 467.66 million Exact value Exact value: -467661000 USD 2019-01-01 – 2019-12-31: -467661000 USD Inspect Net Income Open source Share or cite Citation for Net Income · AMAG PHARMACEUTICALS, INC. · 2019-12-31 AMAG PHARMACEUTICALS, INC. (edgar:792977) Net Income: -467661000 USD Concept: fundies:NetIncome Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T11:54:01Z Snapshot: 7ec3776b1086194e1be37aed54cd06568891eaee4d6ff4b3090d5b728b90d4d5 Dimensions: Consolidated View: https://fundies.io/companies/edgar/792977/explain?concept=fundies%3ANetIncome&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:NetIncome: -467661000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/792977/000079297720000090/a201910-ka.htm#3184701 Filing: 000079297720000090 The citation records this snapshot. The page link may show a newer release later.	−USD 125.7 million Exact value Exact value: -125696000 USD 2019-01-01 – 2019-12-31: -125696000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · AMAG PHARMACEUTICALS, INC. · 2019-12-31 AMAG PHARMACEUTICALS, INC. (edgar:792977) Operating Cash Flow: -125696000 USD Concept: fundies:OperatingCashFlow Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T11:54:01Z Snapshot: 7ec3776b1086194e1be37aed54cd06568891eaee4d6ff4b3090d5b728b90d4d5 Dimensions: Consolidated View: https://fundies.io/companies/edgar/792977/explain?concept=fundies%3AOperatingCashFlow&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -125696000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/792977/000079297720000090/a201910-ka.htm#1421976 Filing: 000079297720000090 The citation records this snapshot. The page link may show a newer release later.	USD 2.54 million Exact value Exact value: 2544000 USD 2019-01-01 – 2019-12-31: 2544000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · AMAG PHARMACEUTICALS, INC. · 2019-12-31 AMAG PHARMACEUTICALS, INC. (edgar:792977) Capital Expenditure: 2544000 USD Concept: fundies:CapitalExpenditure Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T11:54:01Z Snapshot: 7ec3776b1086194e1be37aed54cd06568891eaee4d6ff4b3090d5b728b90d4d5 Dimensions: Consolidated View: https://fundies.io/companies/edgar/792977/explain?concept=fundies%3ACapitalExpenditure&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 2544000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/792977/000079297720000090/a201910-ka.htm#1443170 Filing: 000079297720000090 The citation records this snapshot. The page link may show a newer release later.	−USD 128.24 million Calculation and evidence -125696000 − 2544000 USD Exact free cash flow: -128240000 USD 2019-01-01 – 2019-12-31: -125696000 USD · Inspect Operating Cash Flow · Source 2019-01-01 – 2019-12-31: 2544000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · AMAG PHARMACEUTICALS, INC. · 2019-12-31 AMAG PHARMACEUTICALS, INC. (edgar:792977) Free cash flow: -128240000 USD Concept: free-cash-flow Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T11:54:01Z Snapshot: 7ec3776b1086194e1be37aed54cd06568891eaee4d6ff4b3090d5b728b90d4d5 Dimensions: Consolidated View: https://fundies.io/companies/edgar/792977?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -125696000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/792977/000079297720000090/a201910-ka.htm#1421976 Filing: 000079297720000090 Input fundies:CapitalExpenditure: 2544000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/792977/000079297720000090/a201910-ka.htm#1443170 Filing: 000079297720000090 The citation records this snapshot. The page link may show a newer release later.

Capital expenditure uses the canonical mapped positive-spending convention. A missing, ambiguous, incompatible, or negative-sign input is left blank. Values use the latest reported version.

Dataset coverage and company identifiers

Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.

223 filings · 3,734 latest values · 3,734 originally reported values

Dataset published 2026-11-02. Source filing dates and reporting periods are shown separately.

Identifiers: 0000792977, 792977, AMAG, edgar:792977

Also known as ADVANCED MAGNETICS INC, AMAG PHARMACEUTICALS INC., AMAG PHARMACEUTICALS, INC., AMAG PHARMACEUTICALS, INC., AMAG Pharmaceuticals, Inc.

AMAG PHARMACEUTICALS, INC.

Latest quarter

Revenue

Operating margin

Operating cash flow

Free cash flow

Reported share-count change

Trailing twelve months

Net income

Company performance

What changed year over year

Revenue

Net income

Operating cash flow

Capital expenditure

Where revenue goes

2019 2019-01-01 – 2019-12-31

Cash

Share of revenue by period

Growth

Profit and cash

Balance sheet

Cash generation